| Wissenschaftl. Titel | A Phase III, randomized, open-label, multicenter study of Lurbinectedin in combination with Atezolizumab compared with Atezolizumab as maintanence therapy in participants with extensive - stage SCLC following first-line induction therapy with carboplatin, Etoposid and Atezolizumab |
| Erkrankung |
Thorax:
Kleinzelliges Lungenkarzinom:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (M, Gauting) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 17.10.2022 Data entry III CCP
geändert 22.11.2022 Data entry III CCP